Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with non-compliance

Table 4 Multivariable logistic regression models for bridging use and overuse of bridging, adjusted for clustering at hospital level

	OR (95% CI)^a
Model 1, All patients
Bridging used (reference: no bridging used)
ICU/CCU stay during admission	4.45 (1.72–11.51)
Second surgery performed	3.21 (0.83–12.49)
Mechanical heart valve	8.10 (2.38–27.50)
Type of 1st surgery (reference category: urologic)
Orthopaedic	1.10 (0.42–2.91)
Gastrointestinal	3.45 (1.21–9.87)
Vascular	3.21 (1.01–10.21)
Other	3.57 (1.14–11.21)
Venous thromboembolism	3.91 (1.57–9.74)
iCVA/TIA	2.49 (1.02–6.11)
Previous bleeding^b	3.59 (0.80–16.17)
Model 2, Low TE risk patients:
Overuse of bridging (reference: compliant use)
Type of 1st surgery (reference category: urologic)
Orthopaedic	3.18 (0.60–16.71)
Gastrointestinal	14.85 (2.69–81.99)
Vascular	13.01 (1.83–92.30)
Other	57.30 (5.27–623.62)
Non-elective surgery	8.67 (1.67–45.14)
Lowest 25th percentile SES	0.33 (0.11–1.02)
VKA reversal agent used	0.22 (0.04–1.16)

CCU cardiac care unit, ICU intensive care unit, iCVA ischaemic cerebrovascular accident, TIA transient ischaemic attack, SES Socioeconomic status, VKA Vitamin-K antagonist
^a Adjusted for clustering at hospital level
^b Any previous bleeding event annotated in the medical record

ISSN: 1477-9560